Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Molecular Partners initiated with an Outperform at Cowen » 16:02
07/12/21
07/12
16:02
07/12/21
16:02
MOLN

Molecular Partners

$19.30 /

+0.23 (+1.21%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore initiated coverage of Molecular Partners with an Outperform rating and $50 price target.

ShowHide Related Items >><<
MOLN Molecular Partners
$19.30 /

+0.23 (+1.21%)

MOLN Molecular Partners
$19.30 /

+0.23 (+1.21%)

07/12/21 RBC Capital
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
06/21/21 H.C. Wainwright
Molecular Partners assumed with a Buy at H.C. Wainwright
  • 16
    Jun
MOLN Molecular Partners
$19.30 /

+0.23 (+1.21%)

Recommendations
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital » 11:17
07/12/21
07/12
11:17
07/12/21
11:17
MOLN

Molecular Partners

$19.74 /

+0.67 (+3.51%)

RBC Capital analyst…

RBC Capital analyst Charles Weston lowered the firm's price target on Molecular Partners to CHF 26 from CHF 28 and keeps an Outperform rating on the shares.

ShowHide Related Items >><<
MOLN Molecular Partners
$19.74 /

+0.67 (+3.51%)

MOLN Molecular Partners
$19.74 /

+0.67 (+3.51%)

07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
06/21/21 H.C. Wainwright
Molecular Partners assumed with a Buy at H.C. Wainwright
  • 16
    Jun
MOLN Molecular Partners
$19.74 /

+0.67 (+3.51%)

Initiation
Molecular Partners assumed with an Outperform at SVB Leerink » 07:41
07/12/21
07/12
07:41
07/12/21
07:41
MOLN

Molecular Partners

$19.07 /

+0.28 (+1.49%)

, NVS

Novartis

$92.73 /

+0.405 (+0.44%)

SVB Leerink analyst Daina…

SVB Leerink analyst Daina Graybosch assumed coverage of Molecular Partners (MOLN) with an Outperform rating and $36 price target, from CHF35, and no longer will cover the Swiss shares. This half of the year, the analyst is focused on interim data from the Phase 2/3 EMPATHY study of ensovibep in ambulatory COVID-19, which could potentially support emergency use authorization and lead to an opt-in by partner Novartis (NVS) that would trigger a $164M or $5 per Molecular Partners share licensing fee for the latter. Beyond that, Graybosch looks for Phase 1 data from the immuno-oncology DARPins MP-0310/AMG-506, MP-0317 and their tetra-specific T cell engager for acute myeloid leukemia.

ShowHide Related Items >><<
NVS Novartis
$92.73 /

+0.405 (+0.44%)

MOLN Molecular Partners
$19.07 /

+0.28 (+1.49%)

MOLN Molecular Partners
$19.07 /

+0.28 (+1.49%)

06/21/21 H.C. Wainwright
Molecular Partners assumed with a Buy at H.C. Wainwright
NVS Novartis
$92.73 /

+0.405 (+0.44%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVS Novartis
$92.73 /

+0.405 (+0.44%)

  • 16
    Jun
NVS Novartis
$92.73 /

+0.405 (+0.44%)

NVS Novartis
$92.73 /

+0.405 (+0.44%)

MOLN Molecular Partners
$19.07 /

+0.28 (+1.49%)

Hot Stocks
Molecular Partners provides update on clinical progress of ensovibep » 05:26
07/08/21
07/08
05:26
07/08/21
05:26
MOLN

Molecular Partners

$19.07 /

-0.45 (-2.31%)

, NVS

Novartis

$91.91 /

+0.375 (+0.41%)

Molecular Partners (MOLN)…

Molecular Partners (MOLN) reported on the clinical progress of its novel antiviral candidate, ensovibep, as part of a presentation with its partner Novartis at the 1st Credit Suisse ESG Forum Switzerland virtual event. Ensovibep is designed to bind and inhibit SARS-CoV-2, the virus that causes COVID-19. Ensovibep is currently being studied in a Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, conducted in collaboration with Novartis (NVS) and a National Institutes of Health, or NIH-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol. During the presentation, management outlined initiation of a subcutaneous program to align with the global registrational studies presently underway using administration via infusion. Initiating this year, the studies will evaluate ensovibep delivered subcutaneously to healthy individuals and subsequently to COVID-19 patients. Subcutaneous administration may increase ease and speed of administration to complement ensovibep's simple, high yield manufacturing process, stability, and potential inhibition of all major viral variants to-date. The EMPATHY study is presently enrolling across 5 countries, with continued expansion expected into additional territories as the evolving pandemic dictates. The ACTIV-3 study is presently enrolling patients in the hospitalized setting for assessment with ensovibep across more than 50 centers in 4 countries. The ACTIV-3 study protocol is open for recruitment in the hospitalized setting across 120 centers presently with more centers to open in the coming months. The program is aimed to be active in countries where the virus has high case numbers and to cover emerging variants on a global level. Finally, and in parallel to the clinical progress updated, ensovibep continues to be evaluated for its potency and inhibition against all emerging and established variants of concern. These evaluations are conducted across multiple laboratories, including the NIH. In vitro data to date show that ensovibep retains full potency and viral inhibition against all known SARS-CoV-2 variants in circulation, including the key Delta variants containing the T478K and K417N mutations, presently a particular concern as it may be associated with higher infectivity rates, even in individuals who are vaccinated.

ShowHide Related Items >><<
NVS Novartis
$91.91 /

+0.375 (+0.41%)

MOLN Molecular Partners
$19.07 /

-0.45 (-2.31%)

06/21/21 H.C. Wainwright
Molecular Partners assumed with a Buy at H.C. Wainwright
NVS Novartis
$91.91 /

+0.375 (+0.41%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVS Novartis
$91.91 /

+0.375 (+0.41%)

  • 16
    Jun
NVS Novartis
$91.91 /

+0.375 (+0.41%)

NVS Novartis
$91.91 /

+0.375 (+0.41%)

MOLN Molecular Partners
$19.07 /

-0.45 (-2.31%)

Over a month ago
Initiation
Molecular Partners assumed with a Buy at H.C. Wainwright » 06:11
06/21/21
06/21
06:11
06/21/21
06:11
MOLN

Molecular Partners

$19.29 /

-0.59 (-2.97%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns assumed coverage of Molecular Partners with a Buy rating and $25 price target. The analyst says the company's "burgeoning early-stage oncology pipeline provides meaningful upside." He views Molecular's earlier-stage oncology portfolio as a potential driver of future upside.

ShowHide Related Items >><<
  • 16
    Jun
MOLN Molecular Partners
$19.29 /

-0.59 (-2.97%)

On The Fly
Opening Day: WalkMe stock price falls following $287M IPO » 08:34
06/19/21
06/19
08:34
06/19/21
08:34
CYT

Cyteir Therapeutics

$17.18 /

+0.18 (+1.06%)

, FEMY

Femasys

$12.45 /

-0.79 (-5.97%)

, AMAM

Ambrx Biopharma

$17.60 /

-0.26 (-1.46%)

, DNAY

Codex DNA

$19.06 /

+0.45 (+2.42%)

, TRMR

Tremor International

$17.92 /

+ (+0.00%)

, ATAI

Atai Life Sciences

$19.50 /

+ (+0.00%)

, IPSC

Century Therapeutics

$22.46 /

+2.98 (+15.30%)

, RERE

AiHuiShou

$16.80 /

-1.56 (-8.50%)

, VERV

Verve Therapeutics

$38.76 /

+7.115 (+22.49%)

, LYEL

Lyell Immunopharma

$16.20 /

-0.6 (-3.57%)

, ISPC

iSpecimen

$7.40 /

+0.29 (+4.08%)

, WKME

WalkMe

$28.83 /

-0.17 (-0.59%)

, MOLN

Molecular Partners

$19.29 /

-0.59 (-2.97%)

, CNVY

Convey Health

$12.20 /

-0.505 (-3.97%)

, ALZN

Alzamend Neuro

$9.01 /

-1.01 (-10.08%)

, FLYW

Flywire

$33.80 /

+1.45 (+4.48%)

, PAY

Paymentus

$29.20 /

-0.53 (-1.78%)

, ZIP

ZipRecruiter

$21.26 /

+0.56 (+2.71%)

, DAWN

Day One Biopharmaceuticals

$21.42 /

+2.1899 (+11.39%)

, FIGS

Figs

$36.55 /

+0.04 (+0.11%)

, OMIC

Singular Genomics

$23.90 /

-0.34 (-1.40%)

, CNTA

Centessa

$24.87 /

-0.57 (-2.24%)

, DIDI

DiDi

$14.23 /

-2.43 (-14.59%)

, QNIU

Qiniu

/

+

, RGCB

Regencell Bioscience

/

+

, ELEV

Elevation Oncology

$13.25 /

+0.61 (+4.83%)

, CMSL

Camposol

/

+

, DNUT

Krispy Kreme

/

+

, YOU

Clear Secure

$42.88 /

+4.28 (+11.09%)

, GS

Goldman Sachs

$348.74 /

-12.86 (-3.56%)

, MS

Morgan Stanley

$84.05 /

-3.86 (-4.39%)

, JPM

JPMorgan

$147.87 /

-3.92 (-2.58%)

, AMZN

Amazon.com

$3,486.78 /

-7.155 (-0.20%)

, F

Ford

$14.52 /

-0.25 (-1.69%)

, SAFO

Save Foods

/

+

, HOOD

Robinhood

/

+

Backed by Insight Venture…

ShowHide Related Items >><<
WKME WalkMe
$28.83 /

-0.17 (-0.59%)

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

FLYW Flywire
$33.80 /

+1.45 (+4.48%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

CYT Cyteir Therapeutics
$17.18 /

+0.18 (+1.06%)

FEMY Femasys
$12.45 /

-0.79 (-5.97%)

AMAM Ambrx Biopharma
$17.60 /

-0.26 (-1.46%)

DNAY Codex DNA
$19.06 /

+0.45 (+2.42%)

TRMR Tremor International
$17.92 /

+ (+0.00%)

ATAI Atai Life Sciences
$19.50 /

+ (+0.00%)

IPSC Century Therapeutics
$22.46 /

+2.98 (+15.30%)

RERE AiHuiShou
$16.80 /

-1.56 (-8.50%)

VERV Verve Therapeutics
$38.76 /

+7.115 (+22.49%)

LYEL Lyell Immunopharma
$16.20 /

-0.6 (-3.57%)

06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
ISPC iSpecimen
$7.40 /

+0.29 (+4.08%)

WKME WalkMe
$28.83 /

-0.17 (-0.59%)

MOLN Molecular Partners
$19.29 /

-0.59 (-2.97%)

06/21/21 H.C. Wainwright
Molecular Partners assumed with a Buy at H.C. Wainwright
CNVY Convey Health
$12.20 /

-0.505 (-3.97%)

ALZN Alzamend Neuro
$9.01 /

-1.01 (-10.08%)

FLYW Flywire
$33.80 /

+1.45 (+4.48%)

06/21/21
Fly Intel: Top five analyst initiations
06/21/21 JPMorgan
Flywire initiated with an Overweight at JPMorgan
06/21/21 Raymond James
Flywire initiated with an Outperform at Raymond James
06/21/21 Raymond James
Flywire initiated with an Outperform at Raymond James
PAY Paymentus
$29.20 /

-0.53 (-1.78%)

06/21/21 JPMorgan
Paymentus initiated with a Neutral at JPMorgan
06/21/21 Raymond James
Paymentus initiated with an Outperform at Raymond James
06/21/21 Baird
Paymentus risk/reward seen positive, Baird starts with Outperform
06/21/21 Wells Fargo
Paymentus initiated with an Overweight at Wells Fargo
ZIP ZipRecruiter
$21.26 /

+0.56 (+2.71%)

06/21/21 JPMorgan
ZipRecruiter initiated with a Neutral at JPMorgan
06/21/21 Evercore ISI
Evercore ISI starts 'differentiated' ZipRecruiter at Outperform
06/21/21 Raymond James
ZipRecruiter initiated with a Strong Buy at Raymond James
DAWN Day One Biopharmaceuticals
$21.42 /

+2.1899 (+11.39%)

06/21/21 Cowen
Cowen starts Day One with Outperform on glioma potential
06/21/21 JPMorgan
Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
FIGS Figs
$36.55 /

+0.04 (+0.11%)

06/21/21 Guggenheim
Figs initiated with a Buy at Guggenheim
06/21/21 Cowen
Cowen starts Figs at Outperform, sees path to market cap over $8B
06/21/21 Cowen
Figs initiated with an Outperform at Cowen
OMIC Singular Genomics
$23.90 /

-0.34 (-1.40%)

06/21/21 Cowen
Cowen starts 'promising' Singular Genomics with Outperform rating
06/21/21 JPMorgan
Singular Genomics initiated with an Overweight at JPMorgan
06/21/21 BofA
Singular Genomics initiated with a Neutral at BofA
06/21/21 Cowen
Singular Genomics initiated with an Outperform at Cowen
CNTA Centessa
$24.87 /

-0.57 (-2.24%)

06/22/21
Fly Intel: Top five analyst initiations
06/22/21 Jefferies
Centessa initiated with a Buy at Jefferies
06/22/21 Morgan Stanley
Centessa initiated with an Overweight at Morgan Stanley
06/22/21 Goldman Sachs
Centessa initiated with a Buy at Goldman Sachs
DIDI DiDi
$14.23 /

-2.43 (-14.59%)

QNIU Qiniu
/

+

RGCB Regencell Bioscience
/

+

ELEV Elevation Oncology
$13.25 /

+0.61 (+4.83%)

CMSL Camposol
/

+

DNUT Krispy Kreme
/

+

YOU Clear Secure
$42.88 /

+4.28 (+11.09%)

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

06/17/21 JMP Securities
Goldman Sachs price target raised to $425 from $400 at JMP Securities
06/16/21 JPMorgan
Goldman Sachs price target raised to $452 from $351 at JPMorgan
06/09/21 Jefferies
Jefferies starts 'too cheap' Goldman Sachs at Buy
06/09/21 Jefferies
Goldman Sachs initiated with a Buy at Jefferies
MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

06/29/21 Evercore ISI
Evercore says Morgan Stanley the 'standout' on capital plan among DFAST banks
06/16/21 JPMorgan
Morgan Stanley price target raised to $105 from $85 at JPMorgan
06/09/21 Jefferies
Jefferies starts 'compelling compounder' Morgan Stanley at Buy
06/09/21 Jefferies
Morgan Stanley initiated with a Buy at Jefferies
JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

06/15/21 BMO Capital
JPMorgan price target trimmed to $139 at BMO Capital on reduced NII view
06/14/21 Evercore ISI
Synchrony price target raised to $56 from $49 at Evercore ISI
06/08/21 Wells Fargo
JPMorgan price target raised to $200 from $195 at Wells Fargo
05/06/21 JMP Securities
Walker & Dunlop price target raised to $130 from $70 at JMP Securities
AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

06/24/21 Cowen
Cowen says vote on first antitrust bill encouraging for big tech
06/24/21 Morgan Stanley
Amazon Prime Day revenue up 7% year-over-year, says Morgan Stanley
06/24/21 Piper Sandler
Amazon Prime Day sales rose 13% over last year, says Piper Sandler
06/22/21 Truist
Wayfair's clearance event looks to capitalize on Prime Day effects, says Truist
F Ford
$14.52 /

-0.25 (-1.69%)

06/29/21 UBS
Ford price target raised to $16 from $13 at UBS
06/22/21 Barclays
Ford price target raised to $17 from $15 at Barclays
06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
05/28/21 Deutsche Bank
Deutsche starts Lordstown with Hold on 'considerable uncertainty'
SAFO Save Foods
/

+

HOOD Robinhood
/

+

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 16
    Jun
  • 16
    Jun
  • 17
    Jun
  • 16
    Jun
  • 27
    May
  • 28
    May
  • 27
    May
  • 27
    May
  • 26
    May
  • 26
    May
  • 26
    May
MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

DIDI DiDi
$14.23 /

-2.43 (-14.59%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

WKME WalkMe
$28.83 /

-0.17 (-0.59%)

SAFO Save Foods
/

+

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

DIDI DiDi
$14.23 /

-2.43 (-14.59%)

DAWN Day One Biopharmaceuticals
$21.42 /

+2.1899 (+11.39%)

CYT Cyteir Therapeutics
$17.18 /

+0.18 (+1.06%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

FIGS Figs
$36.55 /

+0.04 (+0.11%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

Syndicate
Molecular Partners opens at $20, IPO priced at $21.25 per ADS » 11:17
06/16/21
06/16
11:17
06/16/21
11:17
MOLN

Molecular Partners

/

+

Molecular Partners (MOLN)…

Molecular Partners (MOLN) priced 3M American Depositary Shares at $21.25. Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.

ShowHide Related Items >><<
  • 16
    Jun
Syndicate
Molecular Partners indicated to open at $20, IPO priced at $21.25 » 10:51
06/16/21
06/16
10:51
06/16/21
10:51
MOLN

Molecular Partners

/

+

Molecular Partners (MOLN)…

Molecular Partners (MOLN) priced 3M American Depositary Shares at $21.25. JPMorgan, SVB Leerink and Cowen acted as joint book running managers for the offering. Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.

ShowHide Related Items >><<
  • 16
    Jun
Syndicate
Molecular Partners 3M share IPO priced at $21.25 » 06:20
06/16/21
06/16
06:20
06/16/21
06:20
MOLN

Molecular Partners

/

+

JPMorgan, SVB Leerink and…

JPMorgan, SVB Leerink and Cowen acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 16
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.